Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Impact van CAR T-celtherapie op effectiviteit mosunetuzumab bij R/R B-cellymfomen
mrt 2025 | Lymfoom